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Abstract
Background: S100B is a calcium-binding protein that is produced primarily by astrocytes. Increased serum S100B
protein levels reflect neurological damage. Autoimmunity may have a role in the pathogenesis of autism in some
patients. Autoantibodies may cross the blood-brain barrier and combine with brain tissue antigens, forming
immune complexes and resulting in neurological damage. We are the first to investigate the relationship between
serum levels of S100B protein, a marker of neuronal damage, and antiribosomal P protein antibodies in autistic
children.
Methods: Serum S100B protein and antiribosomal P antibodies were measured in 64 autistic children in
comparison to 46 matched healthy children.
Results: Autistic children had significantly higher serum S100B protein levels than healthy controls (P < 0.001).
Children with severe autism had significantly higher serum S100B protein than patients with mild to moderate
autism (P = 0.01). Increased serum levels of antiribosomal P antibodies were found in 40.6% of autistic children.
There were no significant correlations between serum levels of S100B protein and antiribosomal P antibodies (P =
0.29).
Conclusions: S100B protein levels were elevated in autistic children and significantly correlated to autistic severity.
This may indicate the presence of an underlying neuropathological condition in autistic patients. Antiribosomal P
antibodies may not be a possible contributing factor to the elevated serum levels of S100B protein in some autistic
children. However, further research is warranted to investigate the possible link between serum S100B protein
levels and other autoantibodies, which are possible indicators of autoimmunity to central nervous system in
autism.
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Introduction
S100 proteins comprise a multitude of low-molecular-
weight, calcium-binding proteins that interact with
other proteins to modulate biological processes [1].
They have been named “S100” because of their bio-
chemical property of remaining soluble after precipita-
tion with 100% ammonium sulfate [2]. S100B protein is
characterized by the presence of two calcium binding
sites of the EF-hand type (helix-loop-helix), one of
which is located in the NH2 terminus and is noncanoni-
cal, whereas the other binding site is located in the
COOH terminus and is canonical. This configuration
enables S100 protein to respond to a calcium stimulus
induced by cell signaling [3]. S100B protein is chiefly
found in glial cells and Schwann cells in the central ner-
vous system (CNS) [4]. The clinical significance of
S100B protein has substantially increased throughout
several areas of clinical neuroscience as it can be used
as a reliable and early predict o ro fp o o rp h y s i o l o g i c a l
and cognitive neurological outcomes [5]. Serum and cer-
ebrospinal fluid (CSF) levels of S100B protein levels are
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reflecting the presence of glial cell pathology and conti-
nuing neurological damage [6-8].
Autoimmunity may play a role in autism in a subgroup
of patients [9,10], as indicated by the presence of brain-
specific autoantibodies in some autistic children [11-17].
These autoantibodies may cross the blood-brain barrier
(BBB) and combine with brain tissue antigens, forming
immune complexes that result in damage of the neurologi-
cal tissue [10]. Also, there is an increase in the frequency
of autoimmune disorders within autistic families [18-23].
In spite of the fact that the origins of autoimmunity in aut-
ism are unknown, in some autistic children there is an
imbalance of T helper 1 (Th1)/Th2 subsets toward Th2,
which are responsible for allergic response and production
of antibodies [9]. Moreover, there is a strong association
between autism and the major histocompatibility complex
for the null allele of C4B in the class III region. This
results in low production of C4B protein, leading to
repeated infections, which play an important role in the
development of autoimmunity [21,24,25].
Various antibodies against neuronal tissues have been
discovered in immune-mediated neurological disorders.
Some of these antibodies have been found to correlate
with the pathomechanism of these diseases [26]. Antiribo-
somal P protein antibodies are one group of potentially
pathogenic autoantibodies that have a specificity for the
functional center of the ribosomal P proteins. These pro-
teins are a family of highly conserved acidic phosphopro-
teins located primarily on the stalk of the large (60s)
ribosomal subunit [27]. They bind three ribosomal pro-
teins, identified as P0, P1 and P2 (38, 19 and 17 kDa,
respectively) by recognizing a certain epitope found in
those three proteins. Several possible pathogenic mechan-
isms for these antibodies in some autoimmune diseases
include their binding to epitopes on the cell membrane
surface, intracellular penetration, inhibition of protein
synthesis, production of proinflammatory cytokines and
induction of cellular apoptosis [28].
In this study, we aimed to investigate the relationship
between serum levels of S100B protein, a marker of neu-
ronal damage, and antiribosomal P protein antibodies as
indicators of the presence of autoimmunity in a group of
autistic children.
Methods
Study population
This cross-sectional study was conducted on 64 children
with autism. They were recruited from the Autism
Research and Treatment Center, Faculty of Medicine,
King Saud University, Riyadh, Saudi Arabia. Patients
were fulfilling the criteria of the diagnosis of autism
according to the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition [29]. The autistic group
comprised 50 males and 14 females. Their ages ranged
from 5 to 12 years (mean ± SD = 8.4 ± 2.5 years).
Exclusions criteria
The exclusion criteria were (1) patients who had asso-
ciated neurological diseases (such as cerebral palsy and
tuberous sclerosis) and metabolic disorders (such as
phenylketonuria); (2) patients with associated allergic,
inflammatory or autoimmune disorders; and (3) patients
who were receiving any medications.
The control group comprised 46 age- and sex-matched,
apparently healthy children (34 males and 12 females).
They were the healthy older siblings of the healthy
infants who attend the Well Baby Clinic, King Khalid
University Hospital, Faculty of Medicine, King Saud Uni-
versity, Riyadh, Saudi Arabia, for routine follow-up of
their growth parameters. The control children were not
related to the children with autism and demonstrated no
clinical findings suggestive of immunological or neurop-
sychiatric disorders. Their ages ranged from 6 to 12 years
(mean ± SD = 9.1 ± 2.4 years). The local ethical commit-
tee of the Faculty of Medicine, King Saud University,
Riyadh, Saudi Arabia, approved this study. In addition, an
informed written consent statement of participation in
the study was signed by the parents or the legal guardians
of the studied subjects.
Study measurements
Clinical evaluation of autistic patients
The evaluation of patients was based on clinical history
taken from caregivers, clinical examination and neurop-
sychiatric assessment. In addition, the degree of the dis-
ease severity was assessedb yu s i n gt h eC h i l d h o o d
Autism Rating Scale (CARS) [30], which rates the child
on a scale from 1 to 4 in each of 15 areas (relating to peo-
ple; emotional response; imitation; body use; object use;
listening response; fear or nervousness; verbal communi-
cation; nonverbal communication; activity level; level and
consistency of intellectual response; adaptation to
change; visual response; taste, smell and touch responses;
and general impressions). According to this scale, chil-
dren who score 30 to 36 have mild to moderate autism
(n = 30) and those with scores ranging from 37 to 60
have a severe degree of autism (n = 34).
Serum assessment of S100B protein
Serum levels of S100B protein were evaluated using an
ELISA kit [31]. To increase accuracy, all samples were
analyzed twice in two independent experiments to assess
the interassay variations and to ensure reproducibility of
the observed results (P >0 . 0 5 ) .N os i g n i f i c a n tc r o s s -
reactivity or interference was observed.
Measurement of serum anti-ribosomal P protein antibodies
Serum total immunoglobulin G (IgG) and IgM antiribo-
somal P protein antibodies were measured by ELISA
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(Nunc-Immuno Module F8 MaxiSorp; Nunc, Roskilde,
Denmark). To increase accuracy, all samples were ana-
lyzed twice in two independent experiments to assess
the interassay variations and to ensure reproducibility of
the observed results (P >0 . 0 5 ) .N os i g n i f i c a n tc r o s s -
reactivity or interference was observed.
Statistical analysis
The results were analyzed by using a commercially avail-
able software package (StatView; Abacus Concepts, Inc,
Berkeley, CA, USA). The data are presented as means ± 2
SD in addition to medians and IQRs, which are between
the 25th and 75th percentiles, for parametric and nonpara-
metric data, respectively. Student’s t-test and the Mann-
Whitney U test were used for comparisons between para-
metric and nonparametric data, respectively. A c
2 test was
used for comparison between qualitative variables of the
studied groups. Spearman’s r correlation coefficient r was
used to determine the relationship between different vari-
ables. For all tests, P < 0.05 was considered significant.
Patients were considered to have elevated serum S100B
protein or antiribosomal P protein antibodies if their levels
were above the highest cutoff values (223.3 pg/ml and
101.3 U/ml, respectively), which were the means ± 2 SD
and 95th percentiles of serum S100B protein and antiribo-
somal P protein levels, respectively, of healthy controls.
Results
Serum S100B protein levels in autistic children and their
relation to the degree of the severity of autism
Autistic children had significantly higher serum S100B
protein levels (207.97 ± 52.6 pg/ml) than healthy con-
trols (171.33 ± 34.65 pg/ml) (P < 0.001) (Figure 1).
Increased serum S100B protein levels were found in 23
(35.9%) of 64 autistic patients.
Patients with severe autism had significantly higher
serum S100B protein levels (222.47 ± 52.95 pg/ml) than
children with mild to moderate autism did (191.53 ± 47.89
pg/ml) (P = 0.01). Although the frequency of increased
serum S100B protein levels was higher in children with
severe autism (44.1%) than in patients with mild to moder-
ate autism (26.7%), this difference did not reach statistical
significance (P = 0.1) (Table 1). In spite of the presence of
positive correlations between serum levels of S100B pro-
tein and CARS in autistic patients, these correlations did
not reach statistical significance (P = 0.055).
Relationship between elevated serum levels of S100B
protein and antiribosomal P protein antibodies in autistic
children
Increased serum levels of antiribosomal P protein anti-
bodies were found in 26 (40.6%) of 64 autistic patients.
Patients with severe autism had significantly higher
serum antiribosomal P protein antibodies [median (IQR)
= 400 (459) U/ml] than children with mild to moderate
autism [median (IQR) = 9 (23) U/ml] (P = 0.01) (Figure
2). Also, the frequency of increased serum antiribosomal
P protein antibodies was significantly higher in children
with severe autism (64.7%) than in patients with mild to
moderate autism (13.3%) (P < 0.001) (Table 1). More-
over, there were significant positive correlations between
serum levels of antiribosomal P protein antibodies and
CARS in autistic patients (P < 0.001) (Figure 3).
Although patients with elevated serum S100B protein
levels had a higher frequency of positivity of serum anti-
ribosomal P protein antibodies (47.8%) than patients
with normal serum S100B protein levels did (36.6%),
this difference did not reach statistical significance (P =
0.27) (Table 2). In addition, serum S100B protein levels
had no significant correlations with serum levels of anti-
ribosomal P protein antibodies (P = 0.29).
Discussion
S100B is an astrocytic calcium-binding protein that has
been proposed as a biochemical marker of brain damage
or dysfunction in acute and chronic neurological diseases
[6]. In our series, autistic children had significantly higher
serum S100B protein levels than healthy controls (P <
0.001). Increased serum S100B protein levels were found
in 35.9% of autistic patients. S100B protein is a marker of
neuronal damage that was first isolated from the CNS in
vertebrates [2], and it is chiefly found in glial cells and
Schwann cells [4]. Researchers in a previous study
Figure 1 Serum levels of S100B protein in children with autism
and healthy children. Mean values are indicated by the horizontal
lines.
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symptoms, induced a statistically significant increment of
about 80% of S100B protein secretion. These data contri-
bute to the proposal that glial cells are targets of risperi-
done [32].
S100B is a protein produced primarily by brain astro-
cytes, and it is an established peripheral biomarker of
altered BBB permeability associated with various CNS
diseases [32,33]. Elevated S100B protein levels accurately
reflect the presence of neuropathological conditions,
including traumatic head injuries [33-35], psychiatric dis-
orders [36], cerebrovascular insults [37] and neurodegen-
erative diseases [38], whereas normal levels reliably
exclude major CNS pathology [35,39,40]. Thus the
increase of serum S100B protein levels in autistic patients
may indicate the presence of an underlying neuropatho-
logical condition.
The potential clinical use of measurement of serum
S100B protein levels in the therapeutic decision-making
process is substantiated by a vast body of literature
validating variations in serum S100B levels with stan-
dard modalities for prognosticating the extent of CNS
damage, alterations in neuroimaging, cerebrospinal pres-
sure and other brain molecular markers (neuron-specific
enolase, glial fibrillary acidic protein) [41,42]. The major
advantage of using S100B levels is that elevations in
serum can be measured easily, providing a sensitive tool
with which to help rule out major CNS dysfunction.
Moreover, as serum S100B levels reflect BBB permeabil-
ity changes even in the absence of neuronal injury
[33-39,43,44], they may increase prior to a significant
change in neurological function or neuronal cell death.
This is an important clinical finding, as the normal
range of S100B levels rules out cerebrovascular damage
and injury to the CNS in nearly 99% of patients by neu-
rological imaging [40,45].
S100B protein is implicated in intracellular and extra-
cellular regulatory activities. Intracellularly, it exhibits
regulatory effects on cell growth, differentiation and
shape, as well as energy metabolism. Extracellularly,
S100B protein stimulates neuronal survival, differentia-
tion, astrocytic proliferation, neuronal death via apoptosis
and regulation of the activity of inflammatory cells [46].
Table 1 Relationship between degree of severity of autism and both elevated serum S100B protein levels and
increased frequency of serum antiribosomal P protein antibodies in autistic children
Protein levels Patients with mild to moderate autism
(n = 30)
Patients with severe autism
(n = 34)
P-value
(c
2 test)
Normal serum S100B protein (n = 41) 22 (73.3%) 19 (55.9%) 0.77
Elevated serum S100B protein (n = 23) 8 (26.7%) 15 (44.1%) (0.27)
Normal serum antiribosomal P protein (n = 38) 26 (86.7%) 12 (35.3%) 17.44
Elevated serum antiribosomal P protein (n = 26) 4 (13.3%) 22 (64.7%) (< 0.001)
In addition, serum S100B protein levels had no significant correlations with the age of the children with autism (P = 0.6).
Figure 2 Serum levels of antiribosomal P protein antibodies in
children with severe autism and healthy children. Median values
are indicated by the horizontal lines.
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Figure 3 Positive correlations between serum levels of
antiribosomal P protein antibodies and CARS in children with
autism. CARS: Childhood Autism Rating Scale.
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neutrophil migration [47]. The degree of systemic inflam-
mation is associated with S100B protein concentration in
acute ischemic stroke [48]. Several studies have suggested
that S100B protein has a role in the pathogenesis of some
autoimmune neuropsychiatric diseases, such as multiple
sclerosis (MS) and neuropsychiatric systemic lupus
erythematosus (NPSLE) [6-8]. Phenotypically and func-
tionally, S100B-specific T cells can be recovered from the
peripheral blood of patients with MS, making S100B a
potential candidate autoantigen in MS [49]. Furthermore,
S100B protein may act as a cytokine [46,50,51], and in
vitro studies have shown that, at high levels, S100B pro-
tein can induce the neuronal expression and secretion of
proinflammatory IL-6. Elevated levels of S100B have
been detected in the CSF of MS patients during acute
phases or exacerbations of the disease [50], and it has
therefore been proposed that elevated S100B protein may
be indicative of active cell injury [51] and can reflect an
axonal and glial pathology. Measurement of serum con-
centrations of S100B protein may be useful for monitor-
ing immunosuppressive therapy and may support clinical
assessment of patients with MS [8]. Serum and CSF
S100B protein levels were raised in patients with NPSLE,
especially among patients with organic brain syndrome,
seizures, cerebral vascular accident and psychosis. This
may imply that S100B protein might serve as an available
and complementary biochemical marker within evalua-
tions of NPSLE. The association of anti-double-stranded
DNA (anti-dsDNA) antibodies with higher S100B protein
levels may indicate that raised serum levels of S100B pro-
tein may reflect continuing neurological damage [6,7,52].
In the present work, patients with severe autism had
significantly higher serum S100B protein levels than chil-
dren with mild to moderate autism (P = 0.01). This may
indicate that the extent of the elevation of serum S100B
protein levels was closely linked to the degree of the
severity of autism. This may be explained by the incre-
ment in the degree of neurological damage with autistic
severity, resulting in more production of S100B protein.
However, it is not easy to determine whether the increase
in serum S100B protein levels is a mere consequence of
autism or has a pathogenic role in the disease.
A possible role of abnormalities in the immune system
in the pathogenesis of autism was previously postulated
[9,10,53,54]. Autoimmunity to the CNS is the common-
est of these abnormalities in autism. This may be indi-
cated by the presence of brain-specific autoantibodies in
some autistic children [9-17]. Immune system dysfunc-
tion may represent a novel target for treatment in aut-
ism [55]. In our series, increased serum levels of
antiribosomal P protein antibodies were found in 40.6%
of autistic patients. Autoantibodies are the hallmark of
autoimmune diseases. We recently reported increased
serum levels of antiribosomal P protein antibodies in
4 4 . 3 %o fa n o t h e rg r o u po f7 0a u t i s t i cc h i l d r e nb e t w e e n
ages 6 and 11 years [56]. This was the only study that in
which the serum levels of these antibodies in autism
were investigated.
Antiribosomal P protein antibodies are highly specific for
SLE, especially for the neuropsychiatric manifestations,
including psychosis, mood disorders, anxiety, cognitive dys-
function and delirium [57]. A recent study has demon-
strated a strong association between the seropositivity of
antiribosomal P protein antibodies and the presence of
neuropsychiatric manifestations in a group of children with
SLE [58]. Some studies in the literature have related antiri-
bosomal P protein antibodies to the pathogenesis of organ
damage in SLE. The main pathways described are cross-
reaction with anti-dsDNA antibodies, a cytotoxic effect on
mesangium cell proliferation, invasion into living cells and
initiation of apoptosis, a defect in the synthesis of apolipo-
protein B resulting in accumulation of lipids inside the cell,
and downregulation of total protein synthesis. P proteins
are posttranslationally modified (dephosphorylated) during
apoptosis, and a dysregulation in the normal clearance of
apoptotic cells leads to aberrant exposure of the immune
system to modified non-self-antigens. This could be one of
the triggering events for the development of anti-P protein
autoimmune response in some autoimmune diseases [57].
Moreover, in an experimental study, mice that received
intracerebroventricular injections of antiribosomal P pro-
tein antibodies developed depression-like behaviors, which
seems to be mediated by specific binding of these antibo-
dies to limbic system brain areas, such as the hippocampus
and the cingulate cortex. It has been proposed that antiri-
bosomal P protein antibodies directly and/or indirectly
affect the CNS and produce a cytotoxic effect on neuronal
cells. The mechanism by which these antibodies cross the
BBB is unknown [59].
Table 2 Relationship between elevated serum S100B protein levels and increased frequency of serum antiribosomal P
protein antibodies in autistic children
Patients with autism
(n = 64)
Normal serum antiribosomal P protein (n = 38) Elevated serum antiribosomal P protein (n = 26) P-value
(c
2 test)
Normal serum S100B protein
(n = 41)
26 (63.4%) 15 (36.6%) 0.77
Elevated serum S100B protein
(n = 23)
12 (52.2%) 11 (47.8%) (0.27)
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cantly higher serum antiribosomal P protein antibodies
than did children with mild to moderate autism (P = 0.01).
Also, the frequency of increased serum antiribosomal P
protein antibodies was significantly higher in children with
severe autism (64.7%) than in patients with mild to moder-
ate autism (13.3%) (P < 0.001). Moreover, there were sig-
nificant positive correlations between serum levels of
antiribosomal P protein antibodies and CARS in autistic
patients (P < 0.001). This might indicate that the extent of
the elevation of serum antiribosomal P protein antibodies
was linked to the degree of severity of autism as assessed
by CARS. The relationship between antiribosomal P pro-
tein antibodies and the severity of autism might be a cau-
sal one in which these autoantibodies might play a role in
the pathogenesis of brain damage, the extent of which
may determine the clinical severity of autism. This war-
rants other studies to reveal the pathogenic role of these
antibodies in autism.
The reason underlying the formation of some autoanti-
bodies in some patients with autism is not fully under-
stood. It is speculated that an autoimmune reaction
might be trigged by cross-reacting antigens in the envir-
onment, resulting in the release of some self-antigens.
These antigens may result in the induction of autoim-
mune reactions through the activation of inflammatory
cells in genetically susceptible individuals [9,10]. The
involvement of the cellular redox state in the pathogen-
esis of autoimmune diseases, including autism, has been
extensively demonstrated. Protein peroxidation confers
alterations in protein structure with impairment of their
functional properties. Proteins with a substantial confor-
mational loss are potential sources of neoantigens, lead-
ing to induction of autoimmunity in a variety of
autoimmune diseases [60,61]. Researchers in a recent
study reported that many autistic children have increased
oxidative stress resulting from enhanced lipid peroxida-
tion and/or a decrease in the level of glutathione peroxi-
dase, which is an important antioxidant. The same
researchers in that study also reported a possible role of
oxidative stress in the induction of autoimmunity in
some autistic patients [62]. Moreover, one study found
that CD4
+CD25
high regulatory T cells were deficient in
73.3% of a group of 30 autistic children [23]. These cells
play an active part in the establishment and maintenance
of immunological self-toler a n c ea n dt h e r e b yp r e v e n t
autoimmunity [63,64]. Thus a deficiency of these cells
may contribute to autoimmunity in a subgroup of autistic
children [23].
Serum S100B protein levels have been reported to be
increased in some autoimmune neuropsychiatric dis-
eases, indicating the presence of underlying neurological
damage [6-8]. Because autoantibodies can cross the BBB
and combine with brain tissue antigens to form immune
complexes that result in neurological damage [10], we
have tried to find a possible link between the elevated
serum levels of S100B protein and antiribosomal P pro-
tein antibodies in autism. In this work, although patients
with elevated serum S100B protein levels had a higher
frequency of positivity of serum antiribosomal P protein
antibodies (47.8%) than patients with normal serum
S100B protein levels did (36.6%), this difference did not
reach statistical significance (P = 0.27).
In addition, serum S100B protein levels had no signifi-
cant correlations with serum levels of antiribosomal P
protein antibodies (P = 0.29). We could not trace data
in the literature to compare our results concerning the
relationship between serum levels of S100B protein and
autoantibodies in autistic patients. This study is the first
to explore such a relationship.
The results of this study may indicate that the presence
of antiribosomal P protein antibodies in some autistic
children may not be a possible contributing factor to
their elevated serum levels of S100B protein. The
increased serum levels of S100B protein may be attributa-
ble to other factors that may participate in neurological
damage in autism. However, this is an initial report that
warrants further research to determine the possible link
between the elevated serum levels of S100B protein and
antiribosomal P protein antibodies in autistic children.
Conclusions
S100B protein levels were elevated in autistic children,
and they were significantly correlated with the degree of
the severity of autism. This may indicate the presence of
an underlying neuropathological condition in autistic
patients. Antiribosomal P protein antibodies might not
be a contributing factor to the elevated serum levels of
S 1 0 0 Bp r o t e i ni ns o m ea u t i s t i cc h i l d r e n .H o w e v e r ,
further research is warranted to investigate the possible
link between serum S100B protein levels and other auto-
antibodies, which are possible indicators of autoimmu-
nity to CNS, in autism.
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